180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial
December 01 2021 - 2:45PM
180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the
“Company”), a clinical-stage biotechnology company focused on the
development of novel drugs that fulfill unmet needs in inflammatory
diseases, fibrosis and pain, today announced that Professor
Jagdeep Nanchahal from the University of Oxford, a co-founder
of 180 Life Sciences, presented a keynote address entitled
‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021
International Dupuytren Symposium on Wednesday, December 1,
2021.
As part of the keynote address, Professor Nanchahal described
how his team unraveled the molecular mechanisms underlying the
pathogenesis of Dupuytren’s disease leading to the identification
of Tumor Necrosis Factor (TNF) as a potential therapeutic target
and clinical trials he led to identify the optimal dose and
formulation of adalimumab, an anti-TNF biologic.
At the keynote, he also disclosed the top line data from the
phase 2b clinical trial, for patients with early-stage disease,
which met the primary end point of nodule hardness and the
secondary end point of nodule size on ultrasound scan with
statistically significant differences. There were no related severe
adverse events. The full results have been submitted for
publication in a peer-reviewed journal and will be disclosed on
publication.
Additional information regarding Prof. Nanchahal’s address,
found in the Current Report on Form 8-K which 180 Life Sciences
filed today with the Securities and Exchange Commission.
The below is a link to the video presentation of Prof.
Nanchahal’s address which will be accessible through the
International Dupuytren website
(https://dupuytrensymposium.org/scientific-program/).
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology
company focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. 180 Life Sciences is leading the research into solving
one of the world’s biggest drivers of disease – inflammation. The
Company is driving groundbreaking studies into clinical programs,
which are seeking to develop novel drugs addressing separate areas
of inflammation for which there are no effective therapies. The
Company’s primary platform is a novel program to treat fibrosis
using anti-TNF (tumor necrosis factor).
Forward-Looking Statements
This press release includes "forward-looking statements",
including information about management’s view of the Company’s
future expectations, plans and prospects, within the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995 (the “Act”). Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,”
“will,” “could,” “should,” “believes,” “predicts,” “potential,”
“continue” and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements
involve significant risks and uncertainties that could cause the
actual results to differ materially from the expected results and,
consequently, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements and factors that may cause such differences include,
without limitation, statements relating to expectations regarding
the capitalization, resources, and funding of the Company;
statements regarding adalimumab’s potential as a treatment for
Dupuytren’s disease; that the top-line data 180 Life Sciences has
reported is based on preliminary analysis of key efficacy and
safety data, and such data may change following a more
comprehensive review of the data related to the clinical trial and
such top-line data may not accurately reflect the complete results
of the trial expectations with respect to future performance,
growth and anticipated acquisitions; the continued listing of the
Company on The NASDAQ Stock Market; expectations regarding the
capitalization, resources and ownership structure of the Company;
expectations with respect to future performance, growth and
anticipated acquisitions; the ability of the Company to execute its
plans to develop and market new drug products and the timing and
costs of these development programs; estimates of the size of the
markets for its potential drug products; potential litigation
involving the Company or the validity or enforceability of the
intellectual property of the Company; global economic conditions;
geopolitical events and regulatory changes; the expectations,
development plans and anticipated timelines for the Company's drug
candidates, pipeline and programs, including collaborations with
third parties; access to additional financing, and the potential
lack of such financing; and the Company’s ability to raise funding
in the future and the terms of such funding. These risk factors and
others are included from time to time in documents the Company
files with the Securities and Exchange Commission, including, but
not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. These
reports and filings are available at www.sec.gov. All subsequent
written and oral forward-looking statements concerning the Company,
the studies described herein or other matters and attributable to
the Company or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.
Readers are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made,
including the forward-looking statements included in this press
release, which are made only as of the date hereof. The Company
cannot guarantee future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance on
these forward-looking statements. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement to reflect
any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based, except as
otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences Corp(678)
570-6791Jason@180lifesciences.com
Media Relations:
Russo PartnersDavid
SchullDavid.Schull@russopartnersllc.com
(212) 845-4271
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Apr 2023 to Apr 2024